TP53 and breast cancer: Of specific interest is the significant OC-LP combined treatment enhancement for the p21 level, which is a p53-independent master effector of multiple tumor suppressor pathways, promoting and justifying the synergistic anti-proliferative effects especially in HER2/estrogen-positive BC [51].